Skip to main content

Table 1 Distribution of endocrine stimulation test according to suspected diagnosis and pathological tests in 2019 and 2020 (a ITT were performed to detect both GHD and CAI simultaneously)

From: Reduction in pediatric growth hormone deficiency and increase in central precocious puberty diagnoses during COVID 19 pandemics

   2019 2020
Suspected diagnosis Stimulation test N of performed tests N of pathological tests % of pathological tests N of performed tests N of pathological tests % of pathological tests
GHD ATT 95 39 41% 60 25 42%
ATT + GHRHT 1 1 100%    
CTT     1 1 100%
ITTa 31 25 81% 19 16 84%
NC-CAH SDST 52 0 0% 56 1 2%
CPP LHRHT 48 24 50% 54 28 52%
CAI ITTa 31 5 16% 19 4 21%
LDST 16 1 6% 13 1 8%
CRHT     1 0 0%
HH LHRHT 18 5 28% 27 1 4%
AGHD ATT + GHRHT 17 0 0% 15 1 7%
CH TRHT     1 1 100%
OG OGTT     4 2 50%
  1. AGHD Adult Growth Hormone Deficiency, ATT Arginine Tolerance Test, ATT + GHRHT Arginine Tolerance Test + Growth Hormone Releasing Hormone Test, CAI Central Adrenal Insufficiency, CH Central Hypothyroidism, CPP Central Precocious Puberty, CRHT Corticotropin-Releasing Hormone Test, CTT Clonidine Tolerance Test, GHD Growth Hormone Deficiency, HH Hypogonadotropic Hypogonadism, ITT Insulin Tolerance Test, LDST Low-Dose Synacthen Test, LHRHT Luteinizing Hormone-Releasing Hormone Test, NC-CAH Non-Classical Congenital Adrenal Hyperplasia, OG OverGrowth, OGTT Oral Glucose Tolerance Test, SDST Standard-Dose Synacthen Test, TRHT Thyrotropin Releasing Hormone